Ipsen And GENFIT Enter Into Exclusive Licensing Agreement For Elafibranor, A Phase III Asset Evaluated In Primary Biliary Cholangitis, As Part Of A Long-Term Global Partnership

Published by
The Street

By Business Wire Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) have entered into a long-term strategic partnership for global collaboration between the two companies. The agreement gives Ipsen exclusive worldwide * license to develop, manufacture and commercialize GENFIT’s investigational treatment elafibranor, for people living with Primary Biliary Chola…

Read More

Leave a Reply